Group 1 - The core point of the article is that Zhonghui Biotech-B (02627) has seen a stock increase of over 7%, currently trading at 50.6 HKD with a transaction volume of 13.64 million HKD, following the approval of its IND application for a recombinant respiratory syncytial virus vaccine by both the National Medical Products Administration (NMPA) in China and the FDA in the United States [1][2]. Group 2 - The company announced that its recombinant respiratory syncytial virus vaccine (CHO cells) utilizes CHO cells to express modified pre-F proteins, achieving a stable high-yield monoclonal cell line that expresses pre-F proteins at higher levels than existing marketed RSV vaccines [1]. - In preclinical studies, the vaccine demonstrated better thermal stability and superior immunogenicity compared to currently available recombinant RSV vaccines [1].
港股异动 中慧生物-B(02627)涨超7% 重组呼吸道合胞病毒疫苗IND申请中美双报获批